We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.
- Authors
Pece, Alfredo; Milani, Paolo; Monteleone, Carla; Trombetta, Costantino; Crecchio, Giuseppe; Fasolino, Giuseppe; Matranga, Domenica; Cillino, Salvatore; Vadalà, Maria
- Abstract
Aims: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). Methods: This was a prospective multicenter randomized nonblinded trial. Results: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an 'on demand' regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls ( p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was 0.52 logMAR (20/63 Seq) and 54 ls, and final BCVA was 0.51 logMar (20/63 Seq) and 57 ls. In group R, mean basal BCVA was 0.62 logMAR (20/80 Seq) and 45 ls, and the final values were 0.50 logMAR (20/63 Seq) and 58 ls. Statistical comparison of the two groups showed no significant difference (logMAR p = 0.90 and letters p = 0.78). Multivariate analysis showed no influence of age or previous photodynamic treatment (PDT) on final visual changes. The mean number of treatments in the first year was 2.7 in group B and 2.3 in group R ( p = 0.09). Conclusion: Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.
- Subjects
BEVACIZUMAB; RANIBIZUMAB; MYOPIA treatment; NEOVASCULARIZATION; DRUG efficacy
- Publication
Graefe's Archive of Clinical & Experimental Ophthalmology, 2015, Vol 253, Issue 11, p1867
- ISSN
0721-832X
- Publication type
Article
- DOI
10.1007/s00417-014-2886-x